This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
Canntab Issued U.S. Patent for Cannabinoid Multilayer Tablets
Company has filed 13 patents in U.S. and Canada.
Canntab Therapeutics Limited has been issued a U.S. patent for its modified-release, multilayer tablet formulations for cannabinoid delivery.
Pursuant to a filing made in March 2017, the U.S. Patent and Trademark Office issued U.S. Patent No. 10,772,837 to Canntab, titled "Modified Release Multi-Layer Tablet Cannabinoid Formulations.” The term of the patent expires on March 15, 2038.